Hudson Bay Capital Management
IONS icon

Hudson Bay Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Hudson Bay Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,000
Closed -$1.48M – 1285
2022
Q2 		$1.48M Hold
40,000
– – 0.01% 864
2022
Q1 		$1.48M Buy
+40,000
New +$1.31M 0.02% 767

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hudson Bay Capital Management's IONS Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Ionis Pharmaceuticals (IONS) stake by 38% in Q1 2026, selling an estimated $14.2M and leaving 295,100 shares worth $22.2M. The position accounts for 0.08% of the portfolio, ranked #176.

Hudson Bay Capital Management first reported a position in IONS in Q1 2018 and has held it in 29 quarters since. The position peaked at $37.6M in Q4 2025. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Hudson Bay Capital Management held 295,100 shares of Ionis Pharmaceuticals worth $22.2M as of Q1 2026.
  • Hudson Bay Capital Management sold 179,900 Ionis Pharmaceuticals shares in Q1 2026, an estimated $14.2M.
  • Ionis Pharmaceuticals made up 0.08% of Hudson Bay Capital Management's portfolio in Q1 2026, its #176 holding.
  • Hudson Bay Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2018 and has held it in 29 quarters since.
  • Hudson Bay Capital Management's Ionis Pharmaceuticals position peaked at $37.6M in Q4 2025.
  • 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.